Science Board discusses CFSAN report
This article was originally published in The Tan Sheet
Executive SummaryFDA's Science Board will discuss an interim report from its subcommittee reviewing research at the Center for Food Safety and Applied Nutrition at a Feb. 22 meeting in Bethesda, Md. The advisory board also will discuss plans to establish a subcommittee to review research at the Center for Drug Evaluation and Research and discuss updates on science programs at the Office of Regulatory Affairs and the National Center for Toxicological Research, according to a Jan. 27 Federal Register 1notice. Oral presentations from the public are scheduled for 1 p.m. to 2 p.m. Requests to make presentations - including the general nature of evidence or arguments to be made, names and addresses of proposed participants, and the approximate time - should be submitted by Feb. 5
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.